{"id":1270,"date":"2025-03-03T00:00:00","date_gmt":"2025-03-03T00:00:00","guid":{"rendered":"https:\/\/www.efhss.com\/pharmacy\/?p=1270"},"modified":"2025-02-27T16:29:09","modified_gmt":"2025-02-27T16:29:09","slug":"eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica","status":"publish","type":"post","link":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/","title":{"rendered":"Eikon recauda casi $351 millones para avanzar en tratamientos contra el c\u00e1ncer en la cl\u00ednica."},"content":{"rendered":"<p>Eikon ha recaudado $1.1 mil millones desde su fundaci\u00f3n en 2019. Cr\u00e9dito: Richard Drury v\u00eda Getty Images.<\/p>\n<p>La empresa biotecnol\u00f3gica estadounidense Eikon Therapeutics ha conseguido $350.7 millones en financiamiento para avanzar en sus tratamientos contra el c\u00e1ncer. Su principal medicamento, EIK1001, es un agonista de los receptores TLR7\/8 que se est\u00e1 probando en un ensayo cl\u00ednico de Fase III para el melanoma avanzado. Este estudio compara la combinaci\u00f3n de EIK1001 con el medicamento Keytruda (pembrolizumab) contra el uso de Keytruda solo como tratamiento inicial. Tambi\u00e9n hay un estudio de Fase II en curso para el c\u00e1ncer de pulm\u00f3n de c\u00e9lulas no peque\u00f1as, que finalizar\u00e1 en 2026.<\/p>\n<p>Eikon adquiri\u00f3 los derechos globales para desarrollar y comercializar EIK1001 tras comprar agentes inmunomoduladores de TLR7\/8 a la empresa Seven and Eight Biotherapeutics en 2023. Seg\u00fan la compa\u00f1\u00eda, EIK1001 ha demostrado ser eficaz solo y en combinaci\u00f3n con otros tratamientos en varios tipos de tumores s\u00f3lidos.<\/p>\n<p>Esta ronda de financiaci\u00f3n es una de las m\u00e1s grandes para una biotecnol\u00f3gica este a\u00f1o. La \u00fanica empresa que ha superado a Eikon hasta ahora es Verdiva Bio, que recaud\u00f3 $410 millones en enero de 2025. Esta empresa se lanz\u00f3 con tres tratamientos licenciados de Sciwind Biosciences de China.<\/p>\n<p>Fundada en 2019, Eikon ya hab\u00eda recaudado $106 millones en una ronda de financiaci\u00f3n en 2023, acumulando un total de $1.1 mil millones. La empresa fue cofundada por el ganador del Premio Nobel Eric Betzig y se enfoca en usar microscop\u00eda de s\u00faper resoluci\u00f3n para seguir el movimiento de prote\u00ednas en c\u00e9lulas vivas. Su plataforma utiliza inteligencia artificial para analizar la din\u00e1mica de las prote\u00ednas, una tecnolog\u00eda que creen podr\u00eda influir en futuros dise\u00f1os de ensayos cl\u00ednicos.<\/p>\n<p>Eikon tambi\u00e9n est\u00e1 desarrollando otros dos medicamentos en estudios de Fase I. EIK1003 es un inhibidor selectivo de PARP1 para tratar c\u00e1nceres de mama, ovario, pr\u00f3stata o p\u00e1ncreas. El segundo, EIK1004, es un inhibidor selectivo de PARP1 para evaluar en c\u00e1ncer cerebral, con un ensayo previsto para 2025, seg\u00fan el CEO de Eikon, Roger Perlmutter.<\/p>\n<p>Adem\u00e1s, Eikon tiene en desarrollo temprano dos antagonistas de receptores de andr\u00f3genos y un inhibidor WRN llamado EIK1005, que se estudia como terapia para pacientes con c\u00e1nceres de alta inestabilidad de microsat\u00e9lites y otros con deficiencias en la reparaci\u00f3n del ADN.<\/p>\n<p>Entre los inversores en esta ronda est\u00e1n Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst y Soros Capital, entre otros.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El principal medicamento candidato de Eikon, el EIK1001, est\u00e1 siendo investigado para tratar el melanoma en combinaci\u00f3n con Keytruda de MSD en un ensayo de Fase III.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[313],"tags":[],"class_list":["post-1270","post","type-post","status-publish","format-standard","hentry","category-uncategorized-es"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eikon recauda casi $351 millones para avanzar en tratamientos contra el c\u00e1ncer en la cl\u00ednica. - International Online Pharmacy<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eikon recauda casi $351 millones para avanzar en tratamientos contra el c\u00e1ncer en la cl\u00ednica. - International Online Pharmacy\" \/>\n<meta property=\"og:description\" content=\"El principal medicamento candidato de Eikon, el EIK1001, est\u00e1 siendo investigado para tratar el melanoma en combinaci\u00f3n con Keytruda de MSD en un ensayo de Fase III.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/\" \/>\n<meta property=\"og:site_name\" content=\"International Online Pharmacy\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eikon recauda casi $351 millones para avanzar en tratamientos contra el c\u00e1ncer en la cl\u00ednica. - International Online Pharmacy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/","og_locale":"en_US","og_type":"article","og_title":"Eikon recauda casi $351 millones para avanzar en tratamientos contra el c\u00e1ncer en la cl\u00ednica. - International Online Pharmacy","og_description":"El principal medicamento candidato de Eikon, el EIK1001, est\u00e1 siendo investigado para tratar el melanoma en combinaci\u00f3n con Keytruda de MSD en un ensayo de Fase III.","og_url":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/","og_site_name":"International Online Pharmacy","article_published_time":"2025-03-03T00:00:00+00:00","author":"author","twitter_card":"summary_large_image","twitter_misc":{"Written by":"author","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/#article","isPartOf":{"@id":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/"},"author":{"name":"author","@id":"https:\/\/www.efhss.com\/pharmacy\/#\/schema\/person\/bd82616b58021f4f263c2ddb64bbd317"},"headline":"Eikon recauda casi $351 millones para avanzar en tratamientos contra el c\u00e1ncer en la cl\u00ednica.","datePublished":"2025-03-03T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/"},"wordCount":452,"commentCount":0,"publisher":{"@id":"https:\/\/www.efhss.com\/pharmacy\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/","url":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/","name":"Eikon recauda casi $351 millones para avanzar en tratamientos contra el c\u00e1ncer en la cl\u00ednica. - International Online Pharmacy","isPartOf":{"@id":"https:\/\/www.efhss.com\/pharmacy\/#website"},"datePublished":"2025-03-03T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.efhss.com\/pharmacy\/es\/eikon-recauda-casi-351-millones-para-avanzar-en-tratamientos-contra-el-cancer-en-la-clinica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.efhss.com\/pharmacy\/"},{"@type":"ListItem","position":2,"name":"Eikon recauda casi $351 millones para avanzar en tratamientos contra el c\u00e1ncer en la cl\u00ednica."}]},{"@type":"WebSite","@id":"https:\/\/www.efhss.com\/pharmacy\/#website","url":"https:\/\/www.efhss.com\/pharmacy\/","name":"International Online Pharmacy","description":"","publisher":{"@id":"https:\/\/www.efhss.com\/pharmacy\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.efhss.com\/pharmacy\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.efhss.com\/pharmacy\/#organization","name":"International Online Pharmacy","url":"https:\/\/www.efhss.com\/pharmacy\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.efhss.com\/pharmacy\/#\/schema\/logo\/image\/","url":"https:\/\/www.efhss.com\/pharmacy\/wp-content\/uploads\/2024\/01\/Logo-IOP.jpg","contentUrl":"https:\/\/www.efhss.com\/pharmacy\/wp-content\/uploads\/2024\/01\/Logo-IOP.jpg","width":100,"height":100,"caption":"International Online Pharmacy"},"image":{"@id":"https:\/\/www.efhss.com\/pharmacy\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.efhss.com\/pharmacy\/#\/schema\/person\/bd82616b58021f4f263c2ddb64bbd317","name":"author","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.efhss.com\/pharmacy\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f40248c4296dc36ffdef8ff0ec5081203b8cda428495941d7a5881c1f7a3e459?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f40248c4296dc36ffdef8ff0ec5081203b8cda428495941d7a5881c1f7a3e459?s=96&d=mm&r=g","caption":"author"},"sameAs":["http:\/\/www.efhss.com"],"url":"https:\/\/www.efhss.com\/pharmacy\/author\/author\/"}]}},"lang":"es","translations":{"es":1270},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/posts\/1270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/comments?post=1270"}],"version-history":[{"count":1,"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/posts\/1270\/revisions"}],"predecessor-version":[{"id":1307,"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/posts\/1270\/revisions\/1307"}],"wp:attachment":[{"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/media?parent=1270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/categories?post=1270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.efhss.com\/pharmacy\/wp-json\/wp\/v2\/tags?post=1270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}